BERKELEY, CA -- (Marketwire) -- 12/17/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2013 at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).
Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact
Source: Dynavax Technologies
News Provided by Acquire Media
